S939 Correlation of Ustekinumab Trough Levels With Outcomes in Inflammatory Bowel Disease

• Published in: The American journal of gastroenterology Vol. 118; no. 10S; pp. S703 - S704
• Main Authors: Petrov, Jessica C., Fine, Sean, Alzahrani, Raneem, Mohamed, Gamal, Al-Bawardy, Badr
• Format: Journal Article
• Language: English
• Published: New York Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.10.2023
• Subjects: Endoscopy; Inflammatory bowel disease; Remission (Medicine); Tumor necrosis factor-TNF
• ISSN: 0002-9270; 1572-0241
• DOI: 10.14309/01.ajg.0000953396.74111.7d

The primary outcomes were the correlation of UST level with clinical remission (per physician global assessment), endoscopic healing (absence of ulcers/erosions in Crohn’s disease (CD) and Mayo endoscopic score ≤ 1 for ulcerative colitis (UC)), and normal serum C-reactive protein (CRP) (≤ 5 mg/L). A cutoff UST level of 4.8 µg/ml yielded the highest area under the curve (AUC) of 0.73 (95% CI: 0.61-0.80) to predict a normal CRP followed by a level cutoff of 3.5 µg/ml which yielded an AUC of 0.66 (95% CI: 0.52- 0.81) to predict endoscopic healing (Table 1). C-reactive protein; AUC: area under the curve; CI: confidence interval Outcomes Cut-Off UST levels (μg/ml) Sensitivity (%) Specificity (%) AUC 95% CI Clinical remission 4.4 52 62 0.62 [0.49-0.75] Endoscopic healing 3.5 76 48 0.66 [0.52-0.81] Normal CRP 4.8 56 87 0.73 [0.61-0.86] Author Notes *Presenter